Among all the psychedelic-addiction signals, psilocybin for smoking cessation is the oldest and one of the most striking. A 2014 Johns Hopkins pilot reported that most participants had quit at six months, an eye-popping figure in a field where cessation tools usually move the needle by single digits. That line of work is now advancing into a NIDA-funded, multi-site Phase 2 trial, which matters on two counts: it marks federal money flowing into psychedelic-addiction research, and it is the test of whether the dramatic pilot effects survive a rigorous, controlled design.
The track record
The 2014 Hopkins open-label pilot, run in long-term smokers with many failed quit attempts behind them, reported that twelve of fifteen participants, about 80 percent, were abstinent at six months, with the majority still abstinent on long-term follow-up. More recently, a larger randomized pilot of 82 smokers compared psilocybin plus therapy against a nicotine patch plus the same therapy, and found roughly 40 percent biochemically verified prolonged abstinence with psilocybin versus about 10 percent with the patch at six months, an odds ratio above six, published this year in a peer-reviewed journal. In a field where a few percentage points of improvement counts as progress, those gaps stand out, which is precisely why they warrant scrutiny rather than celebration.
The Phase 2
The current trial is a multi-site, double-blind, randomized Phase 2 across Johns Hopkins, the University of Alabama at Birmingham, and New York University, testing psilocybin against niacin as an active placebo, with both arms receiving cognitive behavioral therapy, in a few dozen participants. It is funded by the National Institute on Drug Abuse, and that detail is itself a signal. The lack of federal support for psychedelic-treatment research has long been the field’s central obstacle, and a government-funded multi-site psilocybin-addiction trial marks a shift in what kind of money is willing to enter the space.
The context the desk has been tracking
This lands inside the broader race to drug addiction by new mechanisms. The GLP-1 class is pushing across substances, with brenipatide moving into smoking-relapse and alcohol and tirzepatide into cannabis and alcohol, all on a reward-modulation thesis. Psychedelics are pushing on a different mechanism entirely, the psilocybin-assisted-therapy model, across tobacco, opioids, and alcohol. For smoking specifically, both paradigms are now in clinical trials at once. Two fundamentally different bets, metabolic-reward pharmacology on one side and psychedelic-assisted psychotherapy on the other, are converging on the same disorders, and tobacco, with its clean biochemical endpoint, is one of the clearest arenas in which to watch them compete.
The blinding problem
Psychedelic cessation trials run into the same methodological wall the desk has flagged across the field: you cannot blind a psychedelic experience. The Phase 2’s niacin control, which produces a physical flush but no psychedelic effect, and the earlier pilot’s nicotine-patch comparator are both attempts to work around it, and both are imperfect. Participants can almost certainly tell whether they had a psychedelic session, and that knowledge inflates apparent effects on a behavior like quitting that is heavily driven by expectancy and motivation. It is the single strongest reason to treat the striking pilot numbers as hypotheses rather than results.
The caveats
They are the familiar psychedelic ones. The dramatic figures come from pilots of 15 and 82 participants, and the Phase 2 remains modest in size, in a field where effect sizes have repeatedly shrunk as trials grew and controls tightened. The blinding problem likely inflates those early effects. The delivery model is demanding: supervised dosing plus structured therapy, not an off-the-shelf aid, which means it must justify its cost and logistics against cheap, scalable, already-effective cessation tools like varenicline, nicotine replacement, and bupropion, leaving its realistic niche as the treatment-resistant smokers who have failed those. And the encouraging recent randomized pilot is recent, and has not yet been replicated at scale.
The frame
Psilocybin for smoking is the psychedelic-addiction story with the longest history and some of the most arresting pilot data, now meeting the harder evidence bar of a federally funded multi-site Phase 2. It is a genuine test, a marker of federal money entering the space, and a clear instance of psilocybin lining up directly against the GLP-1 class in the contest to treat addiction by new mechanisms. But the caveats apply in full: small numbers, a blind the experience breaks, and a supervised-therapy model that has to earn its cost against cheap incumbents. Smoking cessation is in some ways the ideal proving ground for the psychedelic-therapy model, a hard-to-treat behavior with a clean biochemical endpoint, effective drugs to beat, and a striking pilot signal to confirm or deflate. If the Phase 2 holds anywhere near the pilot numbers, psilocybin has a real case in an indication that measures success unambiguously. If it regresses toward the mean, it becomes an object lesson in how much of the early enthusiasm was the unblinded experience talking. Either way, it is one of the more informative readouts the field has coming.